Halozyme Therapeutics, Inc. (HALO) Revenue & EPS Growth Rates 2026

Growth Analysis - HALO

Financial Metrics

Revenue Trends

Period:

CAGR Performance

Revenue

1Y Growth37.55%

5Y CAGR39.16%

10Y CAGR26.32%

Net Income

1Y Growth-28.64%

5Y CAGR19.68%

10Y CAGRN/A

EPS

1Y Growth-24.57%

5Y CAGR22.68%

10Y CAGRN/A

EBIT

1Y Growth-15.69%

5Y CAGR27.44%

10Y CAGRN/A

EBITDA

1Y Growth-12.72%

5Y CAGR30.23%

10Y CAGRN/A

Capex

1Y Growth-34.84%

5Y CAGR22.72%

10Y CAGR11.44%

Equity

1Y Growth-86.58%

5Y CAGR-20.22%

10Y CAGR1.28%

Cash Flow

1Y Growth36.01%

5Y CAGR63.68%

10Y CAGRN/A

Historical CAGR

Year	1Y CAGR	2Y CAGR	3Y CAGR	5Y CAGR	10Y CAGR	15Y CAGR	20Y CAGR	30Y CAGR
FY 2025 Dec 31, 2025	37.6%	29.8%	28.4%	39.2%	26.3%	36.2%	59.2%	N/A
FY 2024 Dec 31, 2024	22.4%	24.0%	31.8%	39.0%	29.7%	33.3%	N/A	N/A
FY 2023 Dec 31, 2023	25.6%	36.8%	45.8%	40.4%	31.2%	35.4%	68.0%	N/A
FY 2022 Dec 31, 2022	48.9%	57.1%	49.9%	15.8%	31.6%	41.0%	56.2%	N/A
FY 2021 Dec 31, 2021	65.7%	50.4%	42.9%	24.8%	23.0%	50.3%	63.2%	N/A
FY 2020 Dec 31, 2020	36.5%	32.7%	-5.5%	14.7%	34.7%	66.5%	N/A	N/A
FY 2019 Dec 31, 2019	29.1%	-21.3%	10.1%	21.1%	30.5%	N/A	N/A	N/A
FY 2018 Dec 31, 2018	-52.0%	1.7%	4.0%	22.6%	33.0%	78.4%	N/A	N/A
FY 2017 Dec 31, 2017	115.8%	53.1%	61.4%	49.5%	55.6%	72.6%	N/A	N/A
FY 2016 Dec 31, 2016	8.6%	39.5%	38.8%	21.2%	65.0%	78.5%	N/A	N/A
FY 2015 Dec 31, 2015	79.3%	57.0%	47.2%	58.2%	100.7%	N/A	N/A	N/A
FY 2014 Dec 31, 2014	37.5%	33.4%	10.3%	40.7%	N/A	N/A	N/A	N/A
FY 2013 Dec 31, 2013	29.5%	-1.2%	59.0%	44.3%	115.2%	N/A	N/A	N/A
FY 2012 Dec 31, 2012	-24.5%	76.3%	45.7%	61.9%	85.5%	N/A	N/A	N/A
FY 2011 Dec 31, 2011	311.7%	102.5%	85.7%	124.6%	116.6%	N/A	N/A	N/A
FY 2010 Dec 31, 2010	-0.3%	24.7%	53.1%	154.7%	N/A	N/A	N/A	N/A
FY 2009 Dec 31, 2009	56.0%	89.7%	140.6%	N/A	N/A	N/A	N/A	N/A
FY 2008 Dec 31, 2008	130.7%	198.8%	309.9%	221.0%	N/A	N/A	N/A	N/A
FY 2007 Dec 31, 2007	287.0%	446.5%	N/A	112.5%	N/A	N/A	N/A	N/A
FY 2006 Dec 31, 2006	671.8%	N/A	236.8%	108.9%	N/A	N/A	N/A	N/A
FY 2005 Dec 31, 2005	N/A	122.5%	13.2%	N/A	N/A	N/A	N/A	N/A
FY 2004 Dec 31, 2004	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2003 Dec 31, 2003	-70.7%	2.0%	N/A	N/A	N/A	N/A	N/A	N/A
FY 2002 Dec 31, 2002	255.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FY 2001 Dec 31, 2001	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Growth Analysis - HALO

Financial Metrics

Revenue Trends

CAGR Performance

Revenue

Net Income

EPS

EBIT

EBITDA

Capex

Equity

Cash Flow

Historical CAGR

More on Halozyme Therapeutics, Inc.

Compare with peers

Explore

Growth Analysis - HALO

Financial Metrics

Revenue Trends

CAGR Performance

Revenue

Net Income

EPS

EBIT

EBITDA

Capex

Equity

Cash Flow

Historical CAGR

More on Halozyme Therapeutics, Inc.

Compare with peers

Explore